Cefuroxime Axetil: A Review of its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Efficacy

Drugs

Volumn 52, Issue 1, 1996, Pages 125-158

  Perry, Caroline M ^a   Brogden, Rex N ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE; MORAXELLA CATARRHALIS; STAPHYLOCOCCI; STREPTOCOCCUS PNEUMONIAE; BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE; NEGIBACTERIA; POSIBACTERIA;

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFACLOR; CEFIXIME; CEFOTIAM; CEFPODOXIME PROXETIL; CEFUROXIME AXETIL; DOXYCYCLINE; ERYTHROMYCIN; PENICILLIN V; SPARFLOXACIN;

ADOLESCENT; ADULT; AEROBIC BACTERIUM; AGE; AGED; ANAEROBIC BACTERIUM; ANAPHYLAXIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERICIDAL ACTIVITY; CLOSTRIDIUM DIFFICILE; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; EOSINOPHILIA; EPIGASTRIC PAIN; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE AEROBIC RODS AND COCCI; GRAM POSITIVE BACTERIUM; HERXHEIMER REACTION; HUMAN; LIVER TOXICITY; NAUSEA; PSEUDOMEMBRANOUS COLITIS; RESPIRATORY TRACT INFECTION; REVIEW; SERUM SICKNESS; SOMNOLENCE; STOMACH PAIN; URINARY TRACT INFECTION; URTICARIA; VOMITING;

AGE FACTORS; BACTERIA; CEFUROXIME; CEPHALOSPORINS; CLINICAL TRIALS; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PRODRUGS;

EID: 0029941986     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652010-00009     Document Type: Review

References (178)

1. Dellamonica P. Cefuroxime axetil. Int J Amimicrob Agents 1994; 4: 23-36
2. Bergogne-Bérézin E. Cefuroxime axetil: structure-activity relationships [in French]. Med Mal Infect 1991 Sep; 21 Suppl.: 7-12
3. Brogden RN, Heel RC, Speight TM, et al. Cefuroxime: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 1979; 17: 233-66
4. Spangler SK, Jacobs MR, Appelbaum PC. In vitro susceptibilites of 185 penicillin-susceptible and resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicilling G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. Antimicrob Agents Chemother 1994; 38 (12): 2902-4
5. Focht J, Klietmann W, Nösner K, et al. In vitro activity of cefuroxime. Efficacy against pathogenic agents of chronic bronchitis and chronic tonsillitis. Munch Med Wochenschr 1990; 66: 226-9
6. Cooper MA, Andrews JM, Wise R. In-vitro activity of PD 131628, a new quinolone antimicrobial agent. J Antimicrob Chemother 1992; 29: 519-27
7. Knapp CC, Washington II JA. In vitro activities of LY163892, cefactor, and cefuroxime. Antimicrob Agents Chemother 1988 Jan; 32 (1): 131-3
8. Liu Y-C, Huang WK, Cheng DL. Antibacterial activity of cefprozil in vitro. Chemotherapy 1995; 41: 427-32
9. Struelens MJ, Nonhoff C, Lontie M, et al. In vitro activity of commonly used oral antimicrobial agents against community isolates of respiratory pathogens. Acta Clin Belg 1991; 46: 283-9
10. Fung-Tomc JC, Huczko E, Stickle T, et al. Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides. Antimicrob Agents Chemother 1995 Feb; 39: 533-8
11. Liñures J, Alonso T, Pérez JL, et al. Decreased susceptibility of penicillin-resistant pneumococci to twentyfour β-lactam antibiotics. J Antimicrob Chemother 1992; 30: 279-88
12. Barry AL, Pfaller MA, Fuchs PC, et al. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrob Agents Chemother 1994 Oct; 38: 2419-25
13. Marshall SA, Jones RN, Murray PR, et al. In-vitro comparison of DU-6859a, a novel fluoroquinolone, with otherquinolones and oral cephalosporins tested against 5086 recent clinical isolates. J Antimicrob Chemother 1993; 32: 877-84
14. Cullmann W, Dick W, Stieglitz M, et al. Comparable evaluation of orally active beta-lactam compounds in ampicillin-resistant gram-positive and gram-negative rods: role of beta-lactamases on resistance. Chemotherapy 1988; 34: 202-15
15. Washington JA, Jones RN, Gerlach EH, et al. Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, celtazidime, and cefuroxime. Antimicrob Agents Chemother 1993; 37 (8): 1696-700
16. Murray PR. Antimicrobial activity of seven oral antibiotics against selected community- and hospital-acquired pathogens. Clin Ther 1991 Mar-Apr; 13: 224-31
17. Amyes SGB, Baird DR, Crook DW, et al. A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogens. J Antimicrob Chemother 1994; 43: 639-48
18. Van Landuyt HW, Boelaert J, Piot P, et al. In vitro activity of temocillin against clinical isolates. Drugs 1985; 29 Suppl. 5: 1-8
19. Nash DR, Flanagan C, Steel LC, et al. Comparison of the activity of cefixime and activities of other oral antibiotics against adult clinical isolates of Moraxella (Branhamella) catarrhalis containing BRO-1 and BRO-2 and Haemophilus influenzae. Antimicrob Agents Chemother 1991 Jan; 35 (1): 192-4
20. Lambert-Zechovsky N, Mariani-Kurkdjian P, Bingen E, et al. In vitro comparison of four oral betalactams against organisms responsible of acule tract infections in children [in French]. Pathol Biol Paris 1988 Jun; 36 (5 Pt 2): 738-41
21. Lemmen SW, Hauer T, Anding K, et al. Serum bactericidal activity against Moraxella catarrhalis and Streptococcus pneumoniae after administration of four oral cephalosporins in healthy volunteers [letter]. J Antimicrob Chemother 1995 Jan; 35: 233-5
22. Laurans G, Gaudio F, Ducroix JP, et al. In vitro activity of cefuroxime against Moraxella (Branhamella) catarrhalis [In French]. Pathol Biol 1991; 39 (5): 391-5
23. Laurans G, Orfila J. Moraxella (Branhamella) catarrhalis and RTI: in vitro activity of cefuroxime [French]. Med Mal Infect 1991; 21: 34-40
24. Balfour JA, Todd PA, Peters DH. Fleroxacin: a review of its pharmacology and therapeutic efficacy in various infections. Drugs 1995; 49 (5): 794-850
25. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing, Document M1 00-S5. 1944 December; 14 (16)
26. Curtis NAC, Orr D, Ross GW, et al. Competition of β-lactam antibiotics for the penicillin-binding proteins of Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella aerogenes. Proteus rettgeri, and Escherichia coli: Comparison with antibacterial activity and effects upon bacterial morphology. Antimicrob Agents Chemother 1979; 16 (3): 325
27. Bauernfeind A, Jungwirth R. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil. Infection 1991 Sep-Oct; 19 (5): 353-62
28. Bryson HM, Brogden RN. Cefetamet pivoxil: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1993 Apr; 45 (4): 589-621
29. Khan MY, Siddiqui Y, Simpson ML, et al. Comparative in vitro activity of cefmenoxime, cefotaxime, cefuroxime, cefoxitin, and penicillin against Neisseria gonorrhoeae. Antimicrob Agents Chemother 1981; 20 (5): 681-2
30. Yoshikawa TT, Shibata SA, Herbert P, et al. In vitro activity of Ro 13-9904, cefuroxime, cefoxilin, and ampicillin against Neisseria gonorrhoeae. Antimicrob Agents Chemother 1980; 28 (2): 355-6
31. Singh KV, Reves RR, Pickering LK, et al. Comparative in vitro activities of amoxicillin-clavulanic acid, cefuroxime, cephalexin, and cephalothin against trimethoprim-resistant Escherichia coli isolated from stools of children attending day-care centers. Antimicrob Agents Chemother 1990 Nov; 34 (11): 2047-9
32. Ridgway GL, Oriel JD. Activity of antimicrobials against Chlamydia trachomatis in vitro. J Antimicrob Chemother 1979; 5: 471-91
33. Dubreuil L, Derriennic M, Sedallian A. Antibacterial activity of cefpodoxime, cefuroxime and cefaclor against strict anaerobic bacteria. Pathol Biol 1990; 38 (5): 343-6
34. Bergogne-Bérézin E, Vallee E, Muller-Serieys C. The role of cefuroxime-axetil in respiratory tract infections (RTIs) [in French]. Therapie 1991 Jul-Aug; 46: 333-7
35. Smith GH. Oral cephalosporins in perspective [see comments]. DICP 1990 Jan; 24: 45-51
36. Sirot J, Chanal C, Petit A, et al. Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated β-lactamases markedly active against third-generation cephalosporins: epidemiological studies. Rev Infect Dis 1988; 10: 850-9
37. Harris AM, Plested SJ, Griffiths JW. Cefuroxime beta-lactamase stability: comparison with other orally administered beta-lactam antibiotics [poster]. 16th International Congress of Chemotherapy; Jun 1989; Jerusalem, Israel.
38. Jorgensen JH, Doern GV, Maher LA, et al. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990; 34 (11): 2075-80
39. Silley P, Monsey D, Harris AM. Model simulation of a single oral dose of cefuroxime axetil and the related in-vitro kill kinetics against four bacterial species. J Antimicrob Chemother 1990 Jan; 25: 83-90
40. Bingen E, Lambert-Zechovsky N, Doit C, et al. Killing kinetics of cefuroxime axetil against Haemophilus influenzae in an in-vitro model simulating serum concentrations profiles after oral administration. J Antimicrob Chemother 1991 Oct; 28: 533-6
41. Harding SM, Williams PE, Ayrton J. Pharmacology of cefuroxime as the 1-acetoxyethyl ester in volunteers. Antimicrob Agents Chemother 1984 Jan; 25: 78-82
42. Kees F, Lukassek U, Naber KG, et al. Comparative investigations on the bioavailability of cefuroxime axetil. Arzneimittel Forschung 1991 Aug; 41: 843-6
43. Jewesson PJ. Pharmaceutical, pharmacokinetic and other considerations for intravenous to oral stepdown therapy. Can J Infect Dis 1995; 6 Suppl. A: 11A-6A
44. Emmerson AM. Cefuroxime axetil. J Antimicrob Chemother 1988 Aug; 22: 101-4
45. Harding S, Harris A, Hassani H. A profile of cefuroxime axetil. Proceedings from a one-day symposium held at the Royal College of Physicians; 1988 April; London
46. Harding S, Walton CA. Bioavailability of cefuroxime axetil. British Society of Antimicrobial Chemotherapy Meeting. Royal College of Physicians; 1987; Edinburgh
47. Adams DH, Wood MJ, Farrell ID, et al. Oral cefuroxime axetil: clinical pharmacology and comparative dose studies in urinary tract infection. J Antimicrob Chemother 1985 Sep; 16: 359-66
48. Carson JWK, Watters K, Taylor K, et al. Clinical trials of cefuroxime axetil in children. J Antimicrob Chemother 1987; 19: 109-12
49. Lang C, Moreland TA, Davey PG. Bioavailability of cefuroxime axetil: comparison of standard and abbreviated methods. J Antimicrob Chemother 1990 Apr; 25: 645-50
50. Harding SM. Comparative pharmacokinetics of pharmacokinetics and suspension. Res Clin Forum 1990; 12 (3): 23-9
51. Williams PE, Harding SM. The absolute bioavailability of oral cefuroxime axetil in male and female volunteers after fasting and after food. J Antimicrob Chemother 1984 Feb; 13: 191-6
52. Finn A, Straughn A, Meyer M, et al. Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm Drug Dispos 1987 Nov-Dec; 8: 519-26
53. James NC, Donn KH, Collins JJ, et al. Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens. Antimicrob Agents Chemother 1991 Sep; 35: 1860-3
54. Konishi K, Suzuki H, Hayashi M. Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function. J Antimicrob Chemother 1993 Mar; 31: 413-20
55. Jones RW, Betmouni S, Harrison ME, et al. Pharmacokinetics of cefuroxime in elderly volunteers following an oral dose of cefuroxime axetil suspension [abstract]. 18th International Congress of Chemotherapy, 1993 Jun-Jul; Stockholm; 333.
56. Walstad R, Vilsvik J, Thurmann Nielsen E, et al. Pharmacokinetics of cefuroxime axetil in patients with LRTI. A profile of cefuroxime axetil. Proceedings of a one-day symposium held at the Royal College of Physicians; 1988 April; London
57. Taylor CJ, Johnson TN. Cefuroxime axetil paediatric suspension: a pharmacokinetic evaluation. Res Clin Forum 1990; 12 (3): 31-6
58. Powell DA, James NC, Ossi MJ, et al. Pharmacokinetics of cefuroxime axetil suspension in infants and children. Antimicrob Agents Chemother 1991 Oct; 35: 2042-5
59. Donn KH, James NC, Powell JR. Bioavailahility of cefuroxime axetil formulations. J Pharm Sci 1994 Jun; 83: 842-4
60. Cowling P, Case CP, MacGowan AP, et al. Cefuroxime axetil in the sick elderly patient. J Antimicrob Chemother 1992 Mar; 29: 350-1
61. Ridgway E, Stewart K, Rai G, et al. The pharmacokinetics of cefuroxime axetil in the sick elderly patient. J Antimicrob Chemother 1991 May; 27: 663-8
62. Veyssier P, Darchis JP, Devillers A. Pharmacokinetics of cefuroxime-axetil after oral administration during six days treatment in elderly patients [in French]. Therapie 1988 Jun-Jul; 43 Suppl 4: 355-9
63. Sommers DK, Van-Wyk M, Williams PE, et al. Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing. Antimicrob Agents Chemother 1984 Mar; 25: 344-7
64. Mackay J, Mackie AE, Palmer JL, et al. Investigations into the mechanism for the improved oral systemic bioavailability of cefuroxime from cefuroxime axetil when taken after food [abstract]. Br J Clin Pharmacol 1992 Feb; 33: 226P-7P
65. Foord RD. Cefuroxime: human pharmacokinetics. Antimicrob Agents Chemother 1976; 9: 741
66. Lund VJ, Sudderick R, Mackay IS. Concentrations of cefuroxime axetil in sinus tissue. Res Clin Forum 1990; 12 (4): 81-6
67. Tan JS, Salstrom SM, File TM. Cefadroxil, cefaclor, cefuroxime: interstitial fluid concentrations determined through a skin window. Adv Ther 1994 May/June; 11 (3): 154-62
68. Haddad Jr J, Isaacson G, Respler DS, et al. Concentration of cefuroxime in serum and middle ear effusion after single dose treatment with cefuroxime axetil. Pediatr Infect Dis J 1991 Apr; 10: 294-8
69. Baldwin DR, Andrews JM, Wise R, et al. Bronchoalveolar distribution of cefuroxime axetil and in-vitro efficacy of observed concentrations against respiratory pathogens. J Antimicrob Chemother 1992 Sep; 30: 377-85
70. Drewelow B, Kock K. Penetration of cefuroxime into bronchial secretions in patients with pneumonia during sequential therapy with cefuroxime/cefuroxime axetil [abstract]. 181h International Congress of Chemotherapy; 1993 Jun-Jul; Stockholm
71. Wise R, Baldwin DR, Honeybourne D, et al. Penetration of antibiotics into the bronchial mucosa - a review. Res Clin Forum 1990; 12 (4)
72. Winter J, Dhillon P. Penetration of cefuroxime into bronchial mucosa following oral administration of cefuroxime axetil [letter]. J Antimicrob Chemother 1991 Apr; 27: 556-8
73. Jetlund O, Thurmann-Nielsen E, Walstad RA. Comparison of the serum and tissue concentrations of cefuroxime from cefuroxime axetil and phenoxymethylpenicillin in patients undergoing tonsillectomy. Int J Clin Pharmacol Res 1991; 11: 1-6
74. Sudderick RM, Lund VJ, Thomson JP, et al. An evaluation of the penetration of cefuroxime axetil into human paranasal sinus tissue. Rhinology 1992 Mar; 30: 11-6
75. Renneberg J, Christensen OM, Thomsen NOB, et al. Cefuroxime concentrations in serum, joint fluid and bone in elderly patients undergoing arthroplasty after administration of cefuroxime axetil. J Antimicrob Chemother 1993 Nov; 32: 751-5
76. Aujard Y, Boucot I, Brahimi N, et al. Comparative efficacy and safety of four-day cefuroxime axetil and ten-day penicillin treatment of group A beta-hemolytic streptococcal pharyngitis in children. Pediatr Infect Dis J 1995 Apr; 14: 295-300
77. Gehanno P, Chiche D. Treatment of group A β-haemolytic streptococcal tonsillitis with cefuroxime axetil for 4 days: a comparative study with penicillin V for 10 days [in French]. Med Mal Infect 1991 Sep; 21 Suppl.: 66-70
78. Gooch III WM, Swenson E, Higbee MD, et al. Cefuroxime axetil and penicillin V compared in the treatment of group A beta-hemolytic streptococcal pharyngitis. Clin Ther 1987; 9: 670-7
79. Gooch III WM, McLinn SE, Aronovitz GH, et al. Efficacy of cefuroxime axetil suspension compared with that of penicillin V suspension in children with group A streplococcal pharyngitis. Antimicrob Agents Chemother 1993 Feb; 37: 159-63
80. Holm S, Henning C, Grahn E. Is penicillin the appropriate treatment for recurrent tonsillopharyngitis? Results from a comparative randomized blind study of cefuroxime axetil and phenoxymethylpenicillin in children. Scand J Infect Dis 1995; 27 (3): 221-8
81. Pichichero ME, Disney FA, Aronovitz GH, et al. A multicenter, randomized, single-blind evaluation of cefuroxime axetil and phenoxymethyl penicillin in the treatment of streptococcal pharyngitis. Clin Pediatr Phila 1987 Sep; 26: 453-8
82. Adam D. Comparative randomised clinical trial of cefuroxime axetil suspension as O.D. (1 × 20 mg/kg/day) versus B.D. (2 × 10 mg/kg/day) administration in children with tonsillopharyngitis [abstract]. 7th European Congress of Clinical Microbiology and Infectious Diseases; 1995; 269
83. Shapiro AM, Bluestone CD. Otitis media reassessed> Up-to-date answers to some basic questions. Postgrad Med 1995; 97 (5): 73-81
84. Gooch III WM, Blair E, Puopolo A, et al. Effectiveness of five days of therapy with cefuroxime axetil suspension for treatment of acute otitis media. Pediatr Infect Dis J 1996; 15: 157-64
85. Lisby-Sutch SM, Nemec-Dwyer MA, Deeter RG, et al. Therapy of otitis media. Clin Pharm 1990; 9: 15-34
86. Adam D. Comparative randomised trial of cefuroxime axetil suspension versus erythromycin suspension in children with otitis media [abstract]. 18th International Congress of Chemotherapy. 1993 Jun-Jul; Stockholm, 298
87. Dellamonica P, Choutet P, Lejeune JM, et al. Efficacy and safety of cefotiam hexetil in the treatment of acute otitis media. A comparative double blind randomized study versus cefuroxime axetil [in French]. Med Mal Infect 1995 Apr; 25: 599-604
88. Dellamonica P, Choutet P, Lejeune JM, et al. Efficacy and safety of cefotiam hexetil in the treatment of chronic otitis media. A comparative double blind randomized study versus cefuroxime axetil [in French]. Med Mal Infect 1995 May; 25: 733-9
89. Begue P, Lacroix J. Cefuroxime axetil and respiratory tract infection: results of a multicenter trial conducted in pediatric offices [in French]. Med Mal Infect 1991 Sep; 21 Suppl.: 75-8
90. Gooch III WM, Blair E, Puopolo A, et al. Clinical comparison of cefuroxime axetil suspension and amoxicillin/clavulanate suspension in the treatment of pediatric patients with acute otitis media with effusion. Clin Ther 1995; 17 (5): 838-51
91. McLinn SE, Moskal M, Goldfarb J, et al. Comparison of cefuroxime axetil and amoxicillin-clavulanate suspensions in treatment of acute otitis media with effusion in children. Antimicrob Agents Chemother 1994 Feb; 38: 315-8
92. Pichichero M, Aronovitz GH, Gooch WM, et al. Comparison of cefuroxime axetil, cefaclor, and amoxicillin-clavulanate potassium suspensions in acute otitis media in infants and children. South Med J 1990 Oct; 83: 1174-7
93. Stahl JP, Archimbaud A. Treatment of acute otitis media in children: comparison of cefuroxime axetil and amoxicillin-clavulanate suspensions [in French]. Med Mal Infect 1995 Feb; 25: 147-53
94. Brodie DP, Griggs JV, Cunningham K. Comparative study of cefuroxime axetil suspension and amoxycillin syrup in the treatment of acute otitis media in general practice. J Int Med Res 1990 May-Jun; 18: 235-9
95. Syrogiannopoulos GA, Goumas PD, Haliotis FA, et al. Cefuroxime axetil in the treatment of acute otitis media in children. J Chemother 1990 Aug; 4: 221-4
96. McLinn SE, Werner K, Cochetto DM. Clinical trial of cefuroxime axetil versus cefaclor for acute otitis media with effusion. Curr Ther Res 1988; 43 (1): 1-11
97. Gehanno P, Lenoir G, Berche P. In vivo correlates for Streptococcus pneumoniae penicillin resistance in acute otitis media. Antimicrob Agents Chemother 1995 Jan; 39: 271-2
98. Brodie DP, Knight S, Cunningham K. Comparative study of cefuroxime axetil and amoxycillin in the treatment of acute sinusitis in general practice. J Int Med Res 1989 Nov-Dec; 17: 547-51
99. Camacho AE, Cobo R, Otte J, et al. Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with acute bacterial maxillary sinusitis. Am J Med 1992 Sep; 93: 271-6
100. Freche C, Fombeur JP, Pappo M. Evaluation of cefuroxime-axetil in the treatment of acute sinusitis in adults. Comparative study with cefaclor [in French]. Therapie 1988 Jun-Jul 4 (43) Suppl. 4: 365-8
101. Freche C, Guetat F, Chatelin A, et al. Efficacy and safety of cefotiam hexetil (CTM) in the treatment of acute sinusitis. Double-blind comparison with cefuroxime axetil. 18th International Congress of Chemotherapy, 1993 Jun-Jul; Stockholm, 358
102. Gehanno P, Boucot I, Chiche D, et al. Treatment of community acquired acute sinusitis: cefuroxime axetil vs cefixime [in French] Med Mal Infect 1991 Sep; 21 Suppl.: 61-5
103. Gehanno P. Treatment of acute purulent sinusitis in adults: a comparison of two sparfloxacin regimens and cefuroxime-axetil [abstract]. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct; New Orleans, 306
104. Pessey JJ, Groupe de TORL, Gilbert P. Efficacy and safety of cefpodoxime proxetil versus cefuroxime axetil in the treatment of patients with acute sinusitis [in French]. Med Mal Infect 1994 Jun; 22 Spec. issue: 686-92
105. Schlenter WW. Cefuroxime axetil versus doxyxycline in the treatment of sinusitis [abstract]. 17th International Congress of Chemotherapy; 1991 Jun; Berlin, 1267
106. Sydnor Jr A, Gwaltney Jr JM, Cocchetto DM. Comparative evaluation of cefuroxime axetil and cefactor for treatment of acute bacterial maxillary sinusitis. Arch Otolaryngol Head Neck Surg 1989 Dec; 115: 1430-3
107. Vogel F. A guide to the treatment of lower respiratory tract infections. Drugs 1995 Jul; 51 (14): 62-72
108. Henry D, Ruoff GE, Rhudy J, et al. Effectiveness of short-course therapy (5 days) with cefuroxime axetil in the treatment of secondary bacterial infections of acute bronchitis. Antimicrob Agents Chemother 1995; 39 (11): 2528-34
109. Higuera F, Hidalgo H, Feris J, et al. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996; 37: 555-64
110. Hugonot R, Hugonot L, Pappo M, et al. Ambulatory treatment with cefuroxime-axetil of patients aged sixty years or more with infectious bronchitis: a comparative study with amoxicillin/clavulanic acid [in French]. Pathol Biol 1990 Jun; 38: 533-7
111. Landau Z, Schlaffer F, Pitlik S. Cefuroxime axetil vs. augmentin for the treatment of acute bronchitis and exacerbation of chronic obstructive pulmonary disease. Isr J Med Sci 1992 Nov; 28: 797-9
112. Schnelle K. Treatment of acute exacerbations of chronic bronchitis: clinical comparison of the antibiotics cefuroxime axetil and amoxicillin/clavulanic acid [in German]. Med Welt 1993 Apr; 44: 293-8
113. Stahl JP, Pappo M. A multicenter randomized trial of cefuroxime-axetil versus amoxicillin with calvulanic acid in community-acquired ENT and lower respiratory tract infections [in French]. Sem Hôp Paris 1989 Feb 2: 247-51
114. Giamarellou H, Koratzanis G, Kosmidis J, et al. A comparative study of cefuroxime axetil and cefaclor in the treatment of lower respiratory tract infections. Glaxo Wellcome Pharmaceuticals (Uxbridge), 1996. (Data on file)
115. Knight S, Harris A, Logan CJL. Efficacy and safety of cefuroxime axetil compared with cefaclor in the treatment of patients with bronchitis in general practice. 6th International Congress for Infectious Diseases. 1994 April; Prague
116. Nolen TM, Phillips HL, Hutchison J, et al. Comparison of cefuroxime axetil and cefaclor for patients with lower respiratory tract infections presenting to a rural family practice clinic. Curr Ther Res 1988 November; 44 (5): 821-29
117. Schleupner CJ, Anthony WC, Tan J, et al. Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections. Arch Intern Med 1988 Feb; 148: 343-8
118. Yangco BG, Lowe J, Nolen TM, et al. A multicenter trial comparing the efficacy and safety of cefuroxime axetil and cefaclor in pneumonia of adults. Clin Ther 1990 Sep-Oct; 12: 440-6
119. Fabel H, Tölch H-U. Cefuroxime axetil versus clarithromycin in the treatment of LRTI [abstract]. 7th European Congress of Clinical Microbiology and Infectious Diseases; 1995: 129
120. Ball P. Efficacy and safety of cefprozil versus other beta-lactam antibiotics in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1994 Oct; 13: 851-6
121. Camus P, Beraud A, Philip-Joel F, et al. Five days' treatment with cefpodoxime proxetil vs 10 days' treatment with cefuroxime-axetil in elderly patients with acute purulent bronchitis [in French]. Med Mal Infect 1994 Jun; 22 Spec. issue: 681-5
122. Chodosh S, Echols R, Kowalsky S, et al. A prospective, randomized, double-blind, comparative study of ciprofloxacin (CIP) and cefuroxime axetil (CFA) for the treatment of acute bacterial exacerbations of chronic bronchitis (AECB) [abstract]. Clin Infect Dis 1995 Sep; 21: 747
123. Nunley R, Watkins M, Cummings L, et al. Loracarbef (L) versus cefuroxime axetil (CA) and amoxicillin/clavulanate (AC) in acute exacerbation of chronic bronchitis (AECB) [abstract]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994: 259
124. Schworer P. Lomefloxacin (LOME) versus cefuroxime axetil (C/A) in the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) [abstract]. J Clin Pharmacol 1993 Oct; 33: 1007
125. Louie TJ. Intravenous to stepdown antibiotic therapy: Another cost-effective strategy in an era of shrinking health care dollars. Can J Infect Dis 1994; 5 Suppl. C: 45C-50C
126. Markham A, Brogden RN. Cefixime: A reviewof its therapeutic efficacy in lower respiratory tract infections. Drugs 1995 Jun; 49 (6): 1007-22
127. Vogel F. Sequential therapy in the hospital management of lower respiratory tract infections [Data on file; Glaxo]. 1995
128. Janknegt R, van der Meer JWM. Antimicrobial practice. Sequential therapy with intravenous and oral cephalosporins. J Antimicrob Chemother 1994; 33: 169-77
129. Barlinski JJ, Kolinski P. Parenteral cefuroxime followed by cefuroxime axetil in thhe treatment of children with community acquired pneumonia. Pediatria Polska 1994; 69 (1): 43-7
130. Shalit I, Dagan R, Engelhard D, et al. Cefuroxime efficacy in pneumonia: sequential short-course IV/oral suspension therapy. Isr J Med Sci 1994 Sep; 30: 684-9
131. Ducroix JP, Martin F, Smail A, et al. Cefuroxime IM followed by cefuroxime axetil PO: evaluation of a therapeutic protocole for the therapy of community acquired respiratory infections in adults [in French]. Med Mal Infect 1991 Sep; 21 Suppl.: 82-6
132. Stille W, Kranz-Jansen M, Maass A-B, et al. Sequential therapy of community acquired pneumonia: intravenous cefuroxime versus intravenous cefuroxime followed by cefuroxime axetil in the treatment of primary pneumoniae [abstract]. 18th International Congress of Chemotherapy; 1993 Jun-Jul, Stockholm
133. Li JT, Zhao MW, Zhang JL, et al. Cefuroxime (CXM) followed by cefuroxime axetil (CAE) vs cefoperazone (CPZ) in the treatment of lower respiratory tract infection (LRTI) [abstract]. 18th International Congress of Chemotherapy, 1993 Jun-Jul: Stockholm, 134.
134. Kohl KF. A multicentre clinical trial to compare antibiotic regime in patients with LRTIs: cefuroxime i.v. followed by cefuroxime axetil vs. cefotiam i.v. [abstract]. 17th International Congress of Chemotherapy; 1991 Jun, Berlin
135. Brambilla C, Kastanakis S, Knight S. Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1992 Feb; 11: 118-24
136. Leigh DA, Joy GE, Tait S, et al. Treatment of acute uncomplicated urinary tract infections with single daily doses of cefuroxime axetil. J Antimicrob Chemother 1989 Feb; 23: 267-73
137. Iravani A, Richard GA. Single-dose cefuroxime axetil versus multiple-dose cefaclor in the treatment of acute urinary tract infections. Antimicrob Agents Chemother 1989 Aug; 33: 1212-6
138. Cox CE, Sherrill JM, Cocchetto DM. Evaluation of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract infections in adults. Curr Ther Res 1987 July; 42 (1): 124-37
139. Naber KG, Koch EMW. Cefuroxime axetil versus ofloxacin for short-term therapy of acute uncomplicated lower urinary tract infections in women. Infection 1993 Jan-Feb; 21: 34-9
140. Cooper J, Raeburn A, Bruinfitt W. Comparative efficacy and tolerability of cephradine and cefuroxime axetil in the treatment of acute dysuria and/or frequency in general practice. Br J Clin Pract 1992; 46 (1): 24-7
141. Vieiralves LFA, Lucena R, Borges CH. Comparative study of cefetamet pivoxil and cefuroxime axetil in complicated urinary tract infections. Drug Invest 1993 Dec; 6: 347-52
142. Williams KJ, Hebblethwaite EM, Brown GW, et al. Cefuroxime axetil in the treatment of uncomplicated UTI: a comparison with cefaclor and augmentin. Drugs Exp Clin Res 1987; 13: 95-9
143. Gooch III WM, Kaminester L, Cole GW, et al. Clinical comparison of cefuroxime axetil, cephalexin and cefadroxil in the treatment of patients with primary infections of the skin or skin structures. Dermatologica 1991 Jul; 183: 36-43
144. Parish LC, Cocchetto DM, Werner K, et al. Cefuroxime axetil in the treatment of cutaneous infections. Int J Dermatol 1987 Jul-Aug; 26: 389-93
145. Jacobs RF, Brown WD, Chartrand S, et al. Evaluation of cefuroxime axetil and cefadroxil suspensions for treatment of pediatric skin infections. Antimicrob Agents Chemother 1992 Aug; 36: 1614-8
146. Gudgeon AC, Vandenburg MJ, Wight LJ, et al. Is oral cefuroxime axetil suitable for the treatment of unidentified bacterial infection of skin and soft tissue? Br J Clin Pract 1987 Oct; 41: 954-6
147. Watts HF, Williams AH, Cox DM. A pilot study of cefuroxime axetil (Zinnat) and Augmentin in the treatment of skin and soft tissue infections in general practice. Clin Trials J 1987; 24 (5): 356-63
148. Gottlieb A, Mills J. Cefuroxime axetil for treatment of uncomplicated gonorrhea. Antimicrob Agents Chemother 1986 Aug; 30: 333-4
149. Reichman RC, Nolte FS, Wolinsky SM, et al. Single-dose cefuroxime axetil in the treatment of uncomplicated gonorrhea: a controlled trial. Sex Transm Dis 1985 Oct-Dec; 12: 184-7
150. Fong IW, Linton W, Simbul M, et al. Comparative clinical efficacy of single oral doses of cefuroxime axetil and amoxicillin in uncomplicated gonococcal infections. Antimicrob Agents Chemother 1986 Aug; 30: 321-2
151. Kinghorn GR, Spencer RC, Smith TK, et al. Comparative study of cefuroxime axetil and procaine penicillin in the treatment of uncomplicated gonorrhoea. Int J STD AIDS 1990 Jul; 1: 285-7
152. Baddour LM, Gibbs RS, Mertz G, et al. Clinical comparison of single-oral-dose cefuroxime axetil and amoxicillin with probenecid for uncomplicated gonococcal infections in women. Antimicrob Agents Chemother 1989 Jun; 33: 801-4
153. Schift R, van-Ulsen J, Ansink-Schipper MC, et al. Comparison of oral treatment of uncomplicated urogenital and rectal gonorrhoea with cefuroxime axetil ester or clavulanic acid potentiated amoxycillin (Augmentin). Genitourin Med 1986 Oct: 62: 313-7
154. Wanas TM, Williams PE. Oral cefuroxime axetil compared with oral ampicillin in treating acute uncomplicated gonorrhoea. Genitourin Med 1986 Aug; 62: 221-3
155. Das RP, Jones K, Robinson AJ, et al. Cefuroxime axetil to treat gonorrhoea [letter]. Genitourin Med 1988 Dec; 64: 394
156. Das R, Bingham JS, Ridgway G, et al. A comparative trial of cefuroxime axetil and ampicillin plus probenecid in the treatment of acute gonococcal infection. 6th Mediterranean Congress of Chemotherapy; 1988 May; Taormina
157. Chaisilwattana P, Osborne NG. Antibiotic treatment of Neisseria gonorrhoeae infections in women. J Gynecol Surg 1994; 10 (1): 55-6
158. Luger SW, Paparone P, Wormser GP, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 1995 Mar; 39: 661-7
159. Nadelman RB, Luger SW, Frank E, et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992 Aug 15; 117: 273-80
160. Steere AC. Harrison's Principles of Internal Medicine. 12th ed. v. l.: McGraw-Hill, Inc, 1992
161. Neubert U, Braun-Falco O, Koch EMW. Comparative randomised trial of cefuroxime axetil (CAE) versus doxycycline (D) in patients with Erythema chronicam migrans [abstract]. 1993 (18th International Congress of Chemotherapy,. 1993: 346)
162. Carbon C, Bons J, Georges D. Prospective study of the clinical safety profile of a new oral antibiotic: cefuroxime-axetil [in French]. Therapie 1988 Jun-Jul 4 Suppl. 43 Suppl. 4: 369-72
163. Olivieri A, Fostini R, Recchia G. Acetoxyethylcefuroxime: a profile of acetoxyethylcefuroxime: an Italian Database analysis. Basi Raz Ter 1990; 20: 775-9
164. Glaxo Pharmaceuticals. Cefuroxime axetil. Prescribing Information. Physicians' Desk Reference, Montvale New Jersey. US, 1995.
165. Marcos Bravo C, Luna Ortiz I, Gonzalez Vazquez R. Hypersensitivity to cefuroxime with good tolerance to other betalactams. Allergy 1995; 50: 359-61
166. Carbon C, Richard A, Bons B. Antibiotic associated pseudomembranous colitis. Results of a study done with 900 gastroenterologists [in FRENCH]. Therapie 1994 Jul-Aug; 49: 325-31
167. McLinn SE. Cefuroxime axetil suspension in the treatment of acute otitis media in children: a comparison with amoxycillin/clavulanic acid. Res Clin Forum 1990; 12 (3): 67-73
168. Hama R, Mori K. High incidence of anaphylactic reactions to cefaclor Lancet 1988; 1: 1331
169. Glaxo Laboratories Limited. Cefuroxime axetil. Prescribing Informalion. Data Sheet Compendium. London, England, UK. 1995
170. Dagan R, Shvartzman P, Liss Z. Variation in acceptance of common oral antibiotic suspensions. Pediatr Infect Dis J 1994 Aug; 13: 686-90
171. Adam D. Introduction. Pediatr Infect Dis J 1995; 14 S5-6
172. Doern GV. Trends in antimicrobial susceplibiliy of bacterial pathogens of the respiratory tract. Am J Med 1995 Dec 29; 99 Suppl. 6B: 3S-7S
173. Kibsey PC, Rennie RP, Rushton JE. Disk diffusion versus broth microdilution susceptibility testing of Haemophilus species and Moraxella catarrhalis using seven oral antimicrobial agents: application of updated susceptibility guidelines of the National Committee for Clinical Laboratory Standards. J Clin Microbiol 1994 Nov; 12: 2786-90
174. Barry B, Gehanno P, Blumen M, et al. Clinical outcome of acute otitis media caused by penumococci with decreased susceptibility to penicillin. Scand J Infect Dis 1994; 26: 446-52
175. Kam KM, Luey KY, Fung SM, et al. Emergence of multiple-antibiotic-resistant Streptococcus pneumoniae in Hong Kong Antimicrob Agents Chemother 1995; 19 (12): 2667-70
176. Jernigan DB, Cetron MS, Breiman RF. Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP): a strategy from the DRSP Working Group. JAMA 1996 Jan 17; 275: 206-9
177. Thornsberry C, Brown SD, Yee YC, et al. Increasing penicillin resistance in Streptococcus pneumoniae in the U.S. Effect on susceptibilty to oral cephalosporins. Infections in Medicine 1991; 10 Suppl. D: 15-24
178. McCracken Jr GH. Emergence of resistant Streptococcus pneumoniae: a problem in pediatrics. Pediatr Infect Dis J 1995; 14 (5): 424-8